KROS

Keros Therapeutics, Inc. (KROS) | Rumor.io

Keros Therapeutics

KROS

Attention (50-day avg)0%

Attention rank (50-day avg)#3,642

Bullish sentiment (50-day avg)75%

Price to earnings ratio4.61

Market capitalization223.7M

Earnings per share-3.22

Dividend yield (TTM)—

Revenue (annual)244.1M

Net income (annual)87M

Social

What share of all stock conversation is about KROS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Oct 15

Keros Therapeutics, Inc. ($KROS) plans to return $375 million in excess capital to stockholders through a tender offer at $17.75 per share.
The tender offer aims to repurchase up to $194 million in value of shares, with the company also committing to distribute 25% of Takeda proceeds through December 31, 2028.
The share repurchase plan is expected to reduce the number of outstanding shares from 40 million to 20 million, potentially increasing EPS accordingly.

Generated by AI

Sentiment

Of the messages about KROS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	83.33% +25.56
Bearish	—	—	0% -100	16.67% -25.56

Bullish· Apr 10

Keros Therapeutics has a significant cash reserve of $555 million on its balance sheet, making it an attractive target for a buyout.
The company's large cash balance, combined with its agreement with Takeda, positions it to fetch a premium in a sale, potentially leading to a significant increase in its market value.
With a large number of shorts to be covered, the stock is poised for a significant gain, making it a bullish opportunity for investors.

Bearish· Jan 15

$KROS has halted all dosing of its TROPOS program due to additional pericardial effusion adverse events, raising concerns about the safety of the treatment.
The company's PAH program has been effectively killed, with the lead drug "065" no longer being pursued in obesity due to potential interference with oocyte maturation/spermatogenesis.
$KROS's stock price has plummeted, with a 74% decline in value over 6 months, and some analysts predicting a potential drop to $1.

Generated by AI

Topics

Of the messages about KROS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	69.4%
Technical Analysis	—	—	0%	22.39%
Analysts	—	—	0%	5.22%
Controversies	—	—	0%	0%
Earnings	—	—	0%	2.99%
Macro	—	—	0%	0%

Announcements· Apr 10

Keros Therapeutics is reviewing strategic alternatives, including a possible sale, to maximize shareholder value.
The company has formed an independent Strategic Committee to oversee the review process, which will consider options such as a sale, business combination, continued pipeline investment, and return of excess capital.
Keros has adopted a limited-duration stockholder rights plan to protect against hostile takeovers, which will become exercisable if an entity acquires 10% or more of the company's outstanding common stock without Board approval.

Technical Analysis· Dec 12

$KROS may retrace to $42-$48 from the current price.
A bounce in $KROS is expected, with potential targets at $22.59 and $28.
$KROS is showing signs of a potential reversal, with support at $16.60 and resistance at $19.10.

Generated by AI

Community

Of the messages about KROS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	50%	51.61%	20.45%
Newcomers	50%	50%	48.39%	79.55%

Jun 9

The company has announced the return of $375 million in excess capital to stockholders, which is roughly $9.25 per share, but the terms and structure of this return are still under consideration.
The company will focus its research on the KER-065 drug, which is a potential treatment for Duchenne Muscular Dystrophy, and has announced plans to pursue its development.
The return of capital has been met with skepticism by some investors, who are concerned that the company may be using this move to appease shareholders and maintain control, rather than genuinely returning value to stockholders.

Generated by AI

LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company’s co

21d agoYahoo Finance

Keros Therapeutics Approves $5 Million Share Buyback

Keros Therapeutics' (KROS) board approved a $5 million share repurchase program following receipt of

22d agoYahoo Finance

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

27d agoYahoo Finance

Keros Therapeutics director Bienaime buys $10,270 in shares

28d agoInvesting.com

Also Discussed

Investors talking about KROS also mention

#	Name	Attention
1	Janux Therapeutics, Inc.JANX	0%0
2	Scholar Rock Holding Corporation Common StockSRRK	0%new
3	Abivax SAABVX	0.01%-0.01
4	Syros Pharmaceuticals Inc.SYRS	0%0
5	Biohaven Ltd.BHVN	0%-0.01
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	APLT - Applied Therapeutics, Inc.	——
8	Aligos Therapeutics, Inc.ALGS	0%new
9	LENZ Therapeutics, Inc.LENZ	0%new
10	Neumora Therapeutics, Inc. Common StockNMRA	0%0

Keros Therapeutics, Inc.

Healthcare
Biotechnology

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases. The company’s work is built around protein- and pathway-based approaches that target disease mechanisms involved in red blood cell and platelet production, iron regulation, and tissue repair. Keros Therapeutics serves the biotechnology and specialty medicine markets, where it contributes to the development of precision therapies for patients with high unmet medical needs.

Website

Location

1050 Waltham Street

Lexington, MA, 02421

United States

Social

What share of all stock conversation is about KROS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Oct 15

Keros Therapeutics, Inc. ($KROS) plans to return $375 million in excess capital to stockholders through a tender offer at $17.75 per share.
The tender offer aims to repurchase up to $194 million in value of shares, with the company also committing to distribute 25% of Takeda proceeds through December 31, 2028.
The share repurchase plan is expected to reduce the number of outstanding shares from 40 million to 20 million, potentially increasing EPS accordingly.

Generated by AI

Sentiment

Of the messages about KROS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	83.33% +25.56
Bearish	—	—	0% -100	16.67% -25.56

Bullish· Apr 10

Keros Therapeutics has a significant cash reserve of $555 million on its balance sheet, making it an attractive target for a buyout.
The company's large cash balance, combined with its agreement with Takeda, positions it to fetch a premium in a sale, potentially leading to a significant increase in its market value.
With a large number of shorts to be covered, the stock is poised for a significant gain, making it a bullish opportunity for investors.

Bearish· Jan 15

$KROS has halted all dosing of its TROPOS program due to additional pericardial effusion adverse events, raising concerns about the safety of the treatment.
The company's PAH program has been effectively killed, with the lead drug "065" no longer being pursued in obesity due to potential interference with oocyte maturation/spermatogenesis.
$KROS's stock price has plummeted, with a 74% decline in value over 6 months, and some analysts predicting a potential drop to $1.

Generated by AI

Topics

Of the messages about KROS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	69.4%
Technical Analysis	—	—	0%	22.39%
Analysts	—	—	0%	5.22%
Controversies	—	—	0%	0%
Earnings	—	—	0%	2.99%
Macro	—	—	0%	0%

Announcements· Apr 10

Keros Therapeutics is reviewing strategic alternatives, including a possible sale, to maximize shareholder value.
The company has formed an independent Strategic Committee to oversee the review process, which will consider options such as a sale, business combination, continued pipeline investment, and return of excess capital.
Keros has adopted a limited-duration stockholder rights plan to protect against hostile takeovers, which will become exercisable if an entity acquires 10% or more of the company's outstanding common stock without Board approval.

Technical Analysis· Dec 12

$KROS may retrace to $42-$48 from the current price.
A bounce in $KROS is expected, with potential targets at $22.59 and $28.
$KROS is showing signs of a potential reversal, with support at $16.60 and resistance at $19.10.

Generated by AI

Community

Of the messages about KROS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	50%	51.61%	20.45%
Newcomers	50%	50%	48.39%	79.55%

Jun 9

The company has announced the return of $375 million in excess capital to stockholders, which is roughly $9.25 per share, but the terms and structure of this return are still under consideration.
The company will focus its research on the KER-065 drug, which is a potential treatment for Duchenne Muscular Dystrophy, and has announced plans to pursue its development.
The return of capital has been met with skepticism by some investors, who are concerned that the company may be using this move to appease shareholders and maintain control, rather than genuinely returning value to stockholders.

Generated by AI

Keros Therapeutics

Social

Oct 15

Sentiment

Bullish· Apr 10

Bearish· Jan 15

Topics

Announcements· Apr 10

Technical Analysis· Dec 12

Community

Jun 9

News

Keros Therapeutics to receive $20M milestone from Takeda

Keros doses first patient in DMD trial of rinvatercept

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Keros Therapeutics Approves $5 Million Share Buyback

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Keros Therapeutics director Bienaime buys $10,270 in shares

Also Discussed

Keros Therapeutics, Inc.

Company Information

Location

News

Keros Therapeutics to receive $20M milestone from Takeda

Keros doses first patient in DMD trial of rinvatercept

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

Keros Therapeutics Approves $5 Million Share Buyback

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Keros Therapeutics director Bienaime buys $10,270 in shares

Also Discussed

Social

Oct 15

Sentiment

Bullish· Apr 10

Bearish· Jan 15

Topics

Announcements· Apr 10

Technical Analysis· Dec 12

Community

Jun 9